Abstract:
This invention is a group of 3-oxa and 4-oxa phenyl-substituted PGE type, PGF type, PGA type and PGB type compounds, and processes for making those. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Description:
CROSS REFERENCE TO RELATED APPLICATIONS 
     This is a division of application Ser. No. 459,759, filed Apr. 11, 1974 now U.S. Pat. No. 3,931,289, which is a continuation of my copending application Ser. No. 185,448, filed Sept. 30, 1971, which was a continuation-in-part of my copending application Ser. No. 103,338 filed Dec. 31, 1970, and now abandoned. 
    
    
     DESCRIPTION OF THE INVENTION 
     This invention relates to novel compositions of matter, to novel methods for producing them, and to novel chemical intermediates useful in those processes. Particularly, this invention relates to certain novel analogs of prostaglandins E 1 , E 2 , F 1 .sub.α, F 1 .sub.β, F 2 .sub.α, F 2 .sub.β, A 1 , A 2 , B 1 , B 2 , and the dihydro derivatives of the PG 1  compounds. These novel analogs each have an oxa oxygen (--O--) in place of the methylene (--CH 2  --) moiety at the 3-position or at the 4-position of the prostanoic acid structure and also have a benzene ring as part of the C-13 to C-20 chain of the prostanoic acid. 
     The essential material for this application, including the background of the invention, the disclosure of the invention, and the description of the preferred embodiments, including Preparations and Examples, is incorporated by reference from U.S. Pat. No. 3,931,289, columns 1-101, inclusive, under the provisions of M.P.E.P. 608.01(p). 
     The following formulas represent the novel 4-oxa phenyl-substituted prostaglandin analogs of this invention: ##STR1## Formulas XII, XIV, XVI, and XVIII represent 4-oxa phenyl-substituted compounds of the PGE type. 
     In those formulas, R 1  is hydrogen, alkyl of one to 8 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, phenyl substituted with one to 3 chloro or alkyl of one to 4 carbon atoms, inclusive, or ethyl substituted in the β-position with 3 chloro, 2 or 3 bromo, or 1, 2, or 3 iodo. R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8  are hydrogen or alkyl of one to 4 carbon atoms, inclusive. The divalent moiety --C n  H 2n  -- represents alkylene of one to 10 carbon atoms, inclusive, with one to 5 carbon atoms, inclusive, between --CHR 2  -- and --O--. The divalent moiety --C m  H 2m  -- represents alkylene of one to 9 carbon atoms, inclusive, with one to 4 carbon atoms, inclusive, between --CHR 2  -- and --O--. The divalent moiety --C p  H 2p  -- represents alkylene of one to 8 carbon atoms, inclusive, with one, 2, or 3 carbon atoms between --CH=CH-- or --C.tbd.C-- and --O--. The divalent moiety --C q  H 2q  -- represents alkylene of one to 7 carbon atoms, inclusive, with 1 or 2 carbon atoms between --CH=CH-- or --C.tbd.C-- and --O--. The moiety --C t  H 2t  -- represents a valence bond, i.e., wherein t is zero, or alkylene of one to 10 carbon atoms, inclusive, i.e., wherein t is one to 10, substituted with zero, one, or 2 fluoro, with one to 7 carbon atoms, inclusive, between --CR 3  OH-- and the ring. When one or 2 fluoro are present as substituents of --C t  H 2t  --, that moiety will contain 2t- 1 or 2t-2 hydrogen atoms, respectively, rather than 2t hydrogen atoms. The symbol T represents alkyl of one to 4 carbon atoms, inclusive, fluoro, chloro, trifluoromethyl, or --OR 9 , wherein R 9  is hydrogen, alkyl of one to 4 carbon atoms inclusive, or tetrahydropyranyl. The symbol s represents zero, one, 2 or 3. Regarding the combination (T) s  attached to the phenyl ring, no more than two T are other than alkyl. Except for that proviso, when two or three T are present as substituents, they are the same or different. 
     The wavy line ˜ in formulas XII, XIV, XVI, and XVIII indicates attachment of the group to the ring in alpha or beta configuration. 
     Formulas XII, XIV, XVI, and XVIII include lower alkanoates, and also pharmacologically acceptable salts when R 1  is hydrogen. 
     Also included in Formulas XII, XIV, XVI, and XVIII are separate isomers wherein the side chain hydroxy is in S or R (epi) configuration. 
     Included in Formula XIV, are both the cis and the trans compounds with respect to the carbon-carbon double bond in the carboxy-terminated side chain. In all of the compounds containing --CH=CR 4  --, that carbon-carbon double bond is in trans configuration, and the chain containing R 4  is attached to the cyclopentane ring in beta configuration in compounds encompassed by Formulas XII, XIV, XVI, and XVIII. 
     The novel 4-oxa phenyl-substituted prostaglandin analogs of this invention include racemic compounds and both optically active enantiomeric forms thereof. As discussed hereinabove, two structural formulas are required to define accurately these racemic compounds. For convenience, only a single structural formula is used, for example, Formulas XII, XIV, XVI, and XVIII, to define the racemic form and both enantiomeric forms of each group of novel prostaglandin analogs. Each formula is, however, to be construed as including said racemic forms and both of said optically active enantiomeric forms.